Tumor Embolization Market [2021-2031] - Size, Share
The Tumor Embolization Market is expected to register a CAGR of 8.9% from 2024 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented By Product Type (NBCA Glue, Microspheres or Microbeads, Microcoils); Indication (Hemangioblastoma, Juvenile Nasal Angiofibroma, Meningioma, Aneurysmal Bone Cyst); End User (Hospitals, Intensive Care Units, Surgical Centers, Cancer Treatment Centers). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Tumor Embolization Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Tumor Embolization Market Segmentation
Product Type- NBCA Glue
- Microspheres or Microbeads
- Microcoils
- Hemangioblastoma
- Juvenile Nasal Angiofibroma
- Meningioma
- Aneurysmal Bone Cyst
- Hospitals
- Intensive Care Units
- Surgical Centers
- Cancer Treatment Centers
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Strategic Insights
Tumor Embolization Market Growth Drivers- Rising Cancer Incidence: Increase in cases of cancer, mainly in the liver, lung, and kidney-the organs mostly at risk-are skyrocketing incidences of development of primary growth-leading base tumor embolization. With many cancers becoming refractory to conventional treatment, the utilization of therapy as thus an increasingly favorable means of treatment is for being minimally invasive, targeted, improved outcome, and decreased complications.
- Minimally Invasive Procedures: Tumor embolization procedures have become known mostly because they are very minimally invasive. In this method, smaller incisions are used for faster recovery times, to cause fewer complications than overall surgery, thus becoming an attractive category for both patients and healthcare providers to submit to such treatment, which leads to exciting increased adoption and growth in the market.
- Technological Advancements in Embolic Agents: Constant improvements in the embolic agents have been drug-eluting beads and microspheres that significantly increase the effectiveness of complex procedures in tumor embolization. By such innovations, tumors are specifically targeted with minimal tissue damage in creating better treatment outcomes. Such advancements further create a better perception about the technique and broaden clinical applications, and will consequently lead to growing market revenue.
- Integration of Artificial Intelligence in Imaging: In the landscape of tumor embolization procedures guided by imaging, the intervention of AI has heralded a great revolution. These components of the technology facilitate tumor identifier accuracy, preparation techniques for embolization, and decision-making during the procedures in real-time, mirroring what their counterparts do in conventional imaging. This has all resulted in better outcomes for patients and wider acceptance of tumor embolization treatment as a possible intervention for future procedures.
- Growth of Outpatient and Same-Day Discharge Procedures: Nevertheless, tumor embolization trends are seriously causing inroads into minimally invasive outpatient-same-day discharge surgery. In fact, more patients having this kind of procedure are discharged in the same day with recovery and less risk without ever actually spending a night. This will prove the need and increasing demand for such a procedure, especially at outpatient care centers.
- Rising Adoption in Emerging Markets: Owing to improved healthcare infrastructure, increased cancer awareness, and the amount of healthcare spending, the momentum for the tumor embolization market is much higher in emerging markets. Advanced options of treatment, such as embolization, gain a warm reception in these countries and therefore give the world market further turn. These also represent the opening up of new avenues of income for device manufacturers and healthcare providers.
- Expanding Clinical Indications: Tumor embolization is being discovered for every imaginable malignancy-including pancreatic and colorectal tumors. As research grows, more clinical applications are likely to be discovered, allowing room to develop and introduce unique embolization devices. It may push device manufacturers and healthcare providers to innovate and create specific embolization solutions. Expansion to different tumor categories may increase the current market size.
- Partnerships and Collaborations in Emerging Markets: By forming partnerships with healthcare providers in the new markets, companies will tap the increasing growing tumor embolization demand in the region. Rising cancer incidences coupled with increasingly accessible healthcare are a feature of the emerging regions. Consequently, partnerships in such regions will provide companies with an opportunity to introduce advanced embolization technology while having an opening for growth in the emergent market rather than simply satisfying demand for cancer therapy.
- Development of Advanced Embolic Materials: New opportunities emerge for developing more efficacious embolic agents, such as biodegradable microspheres and advanced drug-eluting beads. New approaches achieve better end results, including fewer side effects and improved targeting of tumors. Companies focusing on developing next-generation embolic materials will find a huge window to take lead in such an extremely fast-growing market.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Tumor Embolization Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Tumor Embolization Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The North America region accounts for highest revenue share tumor embolization market
The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional
/
country-wise market wherein 2021-2022 are the historic years, 2023 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%)
MICROVENTION INC., KANEKA PHARMA EUROPE NV GERMAN BRANCH ,PENUMBRA, INC ,DEPUY SYNTHES ,COOK ,DEUTSCHLAND GMBH AND CO. KG ,BOSTON SCIENTIFIC CORPORATION ,BALT EXTRUSION ,ANGIODYNAMICS ,VARIAN MEDICAL SYSTEMS, INC. are the some of the key market players operating in the tumor embolization market
The market is expected to grow at a CAGR of 8.9%
Rising cancer incidence and minimally invasive procedures are the major factors boosting the tumor embolization market growth
Asia Pacific is estimated to grow at the highest CAGR over the forecast year (2023 - 2031)
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Tumor Embolization Market - By Product Type
1.3.2 Tumor Embolization Market - By Indication
1.3.3 Tumor Embolization Market - By End User
1.3.4 Tumor Embolization Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. TUMOR EMBOLIZATION MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. TUMOR EMBOLIZATION MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. TUMOR EMBOLIZATION MARKET - GLOBAL MARKET ANALYSIS
6.1. TUMOR EMBOLIZATION - GLOBAL MARKET OVERVIEW
6.2. TUMOR EMBOLIZATION - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. TUMOR EMBOLIZATION MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. NBCA GLUE
7.3.1. Overview
7.3.2. NBCA Glue Market Forecast and Analysis
7.4. MICROSPHERES OR MICROBEADS
7.4.1. Overview
7.4.2. Microspheres or Microbeads Market Forecast and Analysis
7.5. MICROCOILS
7.5.1. Overview
7.5.2. Microcoils Market Forecast and Analysis
8. TUMOR EMBOLIZATION MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. HEMANGIOBLASTOMA
8.3.1. Overview
8.3.2. Hemangioblastoma Market Forecast and Analysis
8.4. JUVENILE NASAL ANGIOFIBROMA
8.4.1. Overview
8.4.2. Juvenile Nasal Angiofibroma Market Forecast and Analysis
8.5. MENINGIOMA
8.5.1. Overview
8.5.2. Meningioma Market Forecast and Analysis
8.6. ANEURYSMAL BONE CYST
8.6.1. Overview
8.6.2. Aneurysmal Bone Cyst Market Forecast and Analysis
9. TUMOR EMBOLIZATION MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. INTENSIVE CARE UNITS
9.4.1. Overview
9.4.2. Intensive Care Units Market Forecast and Analysis
9.5. SURGICAL CENTERS
9.5.1. Overview
9.5.2. Surgical Centers Market Forecast and Analysis
9.6. CANCER TREATMENT CENTERS
9.6.1. Overview
9.6.2. Cancer Treatment Centers Market Forecast and Analysis
10. TUMOR EMBOLIZATION MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Tumor Embolization Market Overview
10.1.2 North America Tumor Embolization Market Forecasts and Analysis
10.1.3 North America Tumor Embolization Market Forecasts and Analysis - By Product Type
10.1.4 North America Tumor Embolization Market Forecasts and Analysis - By Indication
10.1.5 North America Tumor Embolization Market Forecasts and Analysis - By End User
10.1.6 North America Tumor Embolization Market Forecasts and Analysis - By Countries
10.1.6.1 United States Tumor Embolization Market
10.1.6.1.1 United States Tumor Embolization Market by Product Type
10.1.6.1.2 United States Tumor Embolization Market by Indication
10.1.6.1.3 United States Tumor Embolization Market by End User
10.1.6.2 Canada Tumor Embolization Market
10.1.6.2.1 Canada Tumor Embolization Market by Product Type
10.1.6.2.2 Canada Tumor Embolization Market by Indication
10.1.6.2.3 Canada Tumor Embolization Market by End User
10.1.6.3 Mexico Tumor Embolization Market
10.1.6.3.1 Mexico Tumor Embolization Market by Product Type
10.1.6.3.2 Mexico Tumor Embolization Market by Indication
10.1.6.3.3 Mexico Tumor Embolization Market by End User
10.2. EUROPE
10.2.1 Europe Tumor Embolization Market Overview
10.2.2 Europe Tumor Embolization Market Forecasts and Analysis
10.2.3 Europe Tumor Embolization Market Forecasts and Analysis - By Product Type
10.2.4 Europe Tumor Embolization Market Forecasts and Analysis - By Indication
10.2.5 Europe Tumor Embolization Market Forecasts and Analysis - By End User
10.2.6 Europe Tumor Embolization Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Tumor Embolization Market
10.2.6.1.1 Germany Tumor Embolization Market by Product Type
10.2.6.1.2 Germany Tumor Embolization Market by Indication
10.2.6.1.3 Germany Tumor Embolization Market by End User
10.2.6.2 France Tumor Embolization Market
10.2.6.2.1 France Tumor Embolization Market by Product Type
10.2.6.2.2 France Tumor Embolization Market by Indication
10.2.6.2.3 France Tumor Embolization Market by End User
10.2.6.3 Italy Tumor Embolization Market
10.2.6.3.1 Italy Tumor Embolization Market by Product Type
10.2.6.3.2 Italy Tumor Embolization Market by Indication
10.2.6.3.3 Italy Tumor Embolization Market by End User
10.2.6.4 Spain Tumor Embolization Market
10.2.6.4.1 Spain Tumor Embolization Market by Product Type
10.2.6.4.2 Spain Tumor Embolization Market by Indication
10.2.6.4.3 Spain Tumor Embolization Market by End User
10.2.6.5 United Kingdom Tumor Embolization Market
10.2.6.5.1 United Kingdom Tumor Embolization Market by Product Type
10.2.6.5.2 United Kingdom Tumor Embolization Market by Indication
10.2.6.5.3 United Kingdom Tumor Embolization Market by End User
10.2.6.6 Rest of Europe Tumor Embolization Market
10.2.6.6.1 Rest of Europe Tumor Embolization Market by Product Type
10.2.6.6.2 Rest of Europe Tumor Embolization Market by Indication
10.2.6.6.3 Rest of Europe Tumor Embolization Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Tumor Embolization Market Overview
10.3.2 Asia-Pacific Tumor Embolization Market Forecasts and Analysis
10.3.3 Asia-Pacific Tumor Embolization Market Forecasts and Analysis - By Product Type
10.3.4 Asia-Pacific Tumor Embolization Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Tumor Embolization Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Tumor Embolization Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Tumor Embolization Market
10.3.6.1.1 Australia Tumor Embolization Market by Product Type
10.3.6.1.2 Australia Tumor Embolization Market by Indication
10.3.6.1.3 Australia Tumor Embolization Market by End User
10.3.6.2 China Tumor Embolization Market
10.3.6.2.1 China Tumor Embolization Market by Product Type
10.3.6.2.2 China Tumor Embolization Market by Indication
10.3.6.2.3 China Tumor Embolization Market by End User
10.3.6.3 India Tumor Embolization Market
10.3.6.3.1 India Tumor Embolization Market by Product Type
10.3.6.3.2 India Tumor Embolization Market by Indication
10.3.6.3.3 India Tumor Embolization Market by End User
10.3.6.4 Japan Tumor Embolization Market
10.3.6.4.1 Japan Tumor Embolization Market by Product Type
10.3.6.4.2 Japan Tumor Embolization Market by Indication
10.3.6.4.3 Japan Tumor Embolization Market by End User
10.3.6.5 South Korea Tumor Embolization Market
10.3.6.5.1 South Korea Tumor Embolization Market by Product Type
10.3.6.5.2 South Korea Tumor Embolization Market by Indication
10.3.6.5.3 South Korea Tumor Embolization Market by End User
10.3.6.6 Rest of Asia-Pacific Tumor Embolization Market
10.3.6.6.1 Rest of Asia-Pacific Tumor Embolization Market by Product Type
10.3.6.6.2 Rest of Asia-Pacific Tumor Embolization Market by Indication
10.3.6.6.3 Rest of Asia-Pacific Tumor Embolization Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Tumor Embolization Market Overview
10.4.2 Middle East and Africa Tumor Embolization Market Forecasts and Analysis
10.4.3 Middle East and Africa Tumor Embolization Market Forecasts and Analysis - By Product Type
10.4.4 Middle East and Africa Tumor Embolization Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Tumor Embolization Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Tumor Embolization Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Tumor Embolization Market
10.4.6.1.1 South Africa Tumor Embolization Market by Product Type
10.4.6.1.2 South Africa Tumor Embolization Market by Indication
10.4.6.1.3 South Africa Tumor Embolization Market by End User
10.4.6.2 Saudi Arabia Tumor Embolization Market
10.4.6.2.1 Saudi Arabia Tumor Embolization Market by Product Type
10.4.6.2.2 Saudi Arabia Tumor Embolization Market by Indication
10.4.6.2.3 Saudi Arabia Tumor Embolization Market by End User
10.4.6.3 U.A.E Tumor Embolization Market
10.4.6.3.1 U.A.E Tumor Embolization Market by Product Type
10.4.6.3.2 U.A.E Tumor Embolization Market by Indication
10.4.6.3.3 U.A.E Tumor Embolization Market by End User
10.4.6.4 Rest of Middle East and Africa Tumor Embolization Market
10.4.6.4.1 Rest of Middle East and Africa Tumor Embolization Market by Product Type
10.4.6.4.2 Rest of Middle East and Africa Tumor Embolization Market by Indication
10.4.6.4.3 Rest of Middle East and Africa Tumor Embolization Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Tumor Embolization Market Overview
10.5.2 South and Central America Tumor Embolization Market Forecasts and Analysis
10.5.3 South and Central America Tumor Embolization Market Forecasts and Analysis - By Product Type
10.5.4 South and Central America Tumor Embolization Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Tumor Embolization Market Forecasts and Analysis - By End User
10.5.6 South and Central America Tumor Embolization Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Tumor Embolization Market
10.5.6.1.1 Brazil Tumor Embolization Market by Product Type
10.5.6.1.2 Brazil Tumor Embolization Market by Indication
10.5.6.1.3 Brazil Tumor Embolization Market by End User
10.5.6.2 Argentina Tumor Embolization Market
10.5.6.2.1 Argentina Tumor Embolization Market by Product Type
10.5.6.2.2 Argentina Tumor Embolization Market by Indication
10.5.6.2.3 Argentina Tumor Embolization Market by End User
10.5.6.3 Rest of South and Central America Tumor Embolization Market
10.5.6.3.1 Rest of South and Central America Tumor Embolization Market by Product Type
10.5.6.3.2 Rest of South and Central America Tumor Embolization Market by Indication
10.5.6.3.3 Rest of South and Central America Tumor Embolization Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL TUMOR EMBOLIZATION MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. TUMOR EMBOLIZATION MARKET, KEY COMPANY PROFILES
13.1. MICROVENTION INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. KANEKA PHARMA EUROPE NV GERMAN BRANCH
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PENUMBRA, INC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. DEPUY SYNTHES
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. COOK
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. DEUTSCHLAND GMBH AND CO. KG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BOSTON SCIENTIFIC CORPORATION
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BALT EXTRUSION
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ANGIODYNAMICS
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. VARIAN MEDICAL SYSTEMS, INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. MICROVENTION INC.
2. KANEKA PHARMA EUROPE NV GERMAN BRANCH
3. PENUMBRA, INC
4. DEPUY SYNTHES
5. COOK
6. DEUTSCHLAND GMBH AND CO. KG
7. BOSTON SCIENTIFIC CORPORATION
8. BALT EXTRUSION
9. ANGIODYNAMICS
10. VARIAN MEDICAL SYSTEMS, INC.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For